ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO874

Long Noncoding RNA DLX6-AS1: A Novel Biomarker of Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Guo, Jia, University of Toledo Medical Center, Toledo, United States
  • Hu, Yifang, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • Gong, Rujun, University of Toledo Medical Center, Toledo, Ohio, United States
  • Liu, Zhangsuo, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Background

A growing body of evidence suggests that lncRNAs act as competing endogenous RNAs or natural microRNA sponges and are involved in diverse human diseases including diabetic kidney disease (DKD). Our previous study showed that LncRNA DLX6-AS1 expression was increased in kidney biopsy specimens from DKD patients. However, whether LncRNA DLX6-AS1 expression is associated with albuminuria in DKD remains unknown and was explored in this study.

Methods

A total of 22 type II diabetic patients without albuminuria (diabetes mellitus group), 43 patients with DKD (microalbuminuria group=20,macroalbuminuria group=23) and 32 healthy controls were enrolled in this study. Blood samples were collected. The levels of LncRNA DLX6-AS1 was estimated by RT-qPCR. The correlation between LncRNA DLX6-AS1 levels and clinical variables was assessed by Spearman correlation analysis. Linear regression was applied to model the relationship between urine albumin/creatinine ratio as the dependent variable and other parameters. ROC analysis was performed and the area under the curve (AUC) was estimated to evaluate the power of LncRNA DLX6-AS1 for predicting DKD.

Results

The four groups were comparable in sex, age and triglyceride levels. No significant difference was noted in duration of diabetes and incidence of diabetic retinopathy among subgroups of diabetes. Compared with healthy controls, the serum levels of lncRNA DLX6-AS1 was decreased in diabetic mellitus group (P<0.05), but was increased in DKD patients (P<0.05). This difference remained statistically different after adjustment for eGFR or HDL-C, as shown by linear regression analysis. In addition, serum LncRNA DLX6-AS1 levels were found to positively correlate with urine albumin/creatinine ratios(rs=0.626,P<0.001), but negatively correlate with eGFR(rs=-0.289,P=0.020). Receiver operating characteristic (ROC) curve analysis was conducted to determine the ability of serum LncRNA DLX6-AS1 levels to serve as biomarkers for predicting DKD. The area under the ROC curve (AUC) was estimated to be 0.879 (95% CI = 0.798 to 0.961), suggestive of an excellent sensitivity and specificity of serum LncRNA DLX6-AS1 levels in predicting DKD.

Conclusion

Serum levels of LncRNA DLX6-AS1 correlate with albuminuria in patients with diabetic kidney disease and may serve as a biomarker for predicting DKD.

Funding

  • Government Support - Non-U.S.